Not yet recruitingInterventionalPhase 1Last updated Aug 10, 2026

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer

Overview

ClinicalTrials.gov ID: NCT07756593
Lead Sponsor: Washington University School of MedicineOTHER
Brief Summary: This phase Ib single-center open-label de-escalation study uses a modified 3+3 design to determine the safety, tolerability, and recommended phase II dose (RP2D) of the combination of standard of care Sip-T and N-803 in patients with metastatic androgen pathway modulation resistant (mAPMR) prostate cancer. Patients will receive treatment for up to 8 weeks.
Study Type

Status

Overall Status: Not yet recruiting
Start Date: Nov 30, 2026Estimated
Primary Completion Date: Apr 14, 2029Estimated
Completion Date: Jan 31, 2031Estimated

Study Record Dates

First Submitted: Aug 6, 2026
First Submitted that Met QC Criteria: Aug 6, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 6, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Aug 2026

NCT01338012Terminated

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

NCT01832870Completed

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

NCT05806814Active, not recruiting

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

NCT00901342Completed

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

NCT01981122Completed

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

NCT06134232Recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T